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Abstract Uroguanylin, a member of the guanylin peptide 
family, is a novel peptide regulator for intestinal salt and water 
transport. A cDNA encoding a precursor for rat uroguanylin was 
cloned from a rat jejunum cDNA library and sequenced. The 
precursor was 106 amino acids long and included a 21 residue 
putative signal peptide at the N-terminus. Rat uroguanylin 
consisted of 15 amino acids similar to, but distinct from human 
uroguanylin; the C-terminal lencine residue was deleted and 3 
residues were substituted compared to those in the human 
peptide. Synthetic rat uroguanylin-15 dose-dependently increased 
the cyclic GMP level in cultured T84 cells. RNA blot analysis 
showed that rat uroguanylin mRNA is expressed not only in the 
gastrointestinal tract but also in the lung, pancreas and kidney. 
Evidence for uroguanylin expression in extra-gastrointestinal 
tissues indicates the possible existence of a novel system for 
water and electrolyte homeostasis, and a more global effect of 
uroguanylin on epithelial cell function. 
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1. Introduction 
Guanylin and uroguanylin are novel peptide regulators for 
intestinal salt and water transport [1-5]. The two peptides 
have 50% amino acid sequence homology and two intramo- 
lecular disulfide bonds in common. Human and opossum uro- 
guanylins have been isolated and sequenced, and their bioac- 
tivities have been analyzed [6-9]. Human uroguanylin, a 16- 
amino acid peptide isolated from urine, stimulates cyclic GMP 
(cGMP) production in enterocytes by activating an apical 
membrane, receptor-guanylate cyclase C (GC-C) [7]. In addi- 
tion, the peptide increased the cGMP level in T84 human 
colon cancer cells that express GC-C, displaced heat-stable 
enterotoxin (ST) binding to GC-C, and stimulated C1- secre- 
tion [7]. Uroguanylin has also been shown to cause natriuretic 
effects in the perfused rat kidney [10,111. Uroguanylin is 
speculated to be a potent physiological regulator of intestinal 
and/or renal fluid and electrolyte transport. 
To understand better its physiological implications and 
pathophysiological significance in water and electrolyte home- 
ostasis, detailed analysis of its cell and tissue distribution is 
required. We report the cloning and sequence analysis of rat 
uroguanylin cDNA. We also used RNA blot analysis to de- 
termined the expression of  the uroguanylin gene. 
2. Materials and methods 
2.1. Tissue preparation 
The stomach, duodenum, jejunum, ileum, colon, liver, pancreas, 
kidney, lung, heart and brain were resected immediately after decap- 
itation of five 8-week-old male Sprague Dawley rats that had fasted 
overnight. The jejunum was resected 40-50 cm from the pyloric ring, 
the ileum 10-20 cm above the terminal ileum and the colon 5-15 cm 
below the terminal ileum. All the rats used were kept in an air-con- 
ditioned room and fed with standard laboratory chow and water ad 
libitum. 
2.2. PCR amplification ofrat uroguanylin cDNA probe 
Complementary DNA prepared from rat jejunum RNA was used in 
each of the series of PCR experiments performed with 10 mM Tris- 
HCI (pH 8.3), 50 mM KC1, 1.5 mM MgC12, 0.001% gelatin, 0.2 mM 
of each dNTP, 1.25 units of Taq DNA polymerase (Perkin-Elmer 
Corp.), and 10 ~tM of each PCR primer. PCR conditions were 35 
cycles of denaturation at 94°C for 30 s, annealing at 48°C for 45 s, 
and extension at 72°C for 1 min. The primers were a series of degen- 
erative oligonucleotides based on the amino acid sequence of human 
uroguanylin [7]. Each of two sense primers was used in the PCR 
reactions with each of four antisense primers. The sense primers 
had the following sequences; 
S|: AA (T/C) GA (T/C) GA (T/C) TG (T/C) GA (A/G) TT (A/G) TG 
$2: AA (T/C) GA (T/C) GA (T/C) TG (T/C) GA (A/G) CTNTG 
and the antisense primers; 
ASI: TANAG (A/G) CANCC (T/C) GT (A/G) CA (T/C) GC 
AS2: TANAG (A/G) CANCC (T/C) GT (A/G) CA (A/G) GC 
AS3: TANAG (A/G) CANCC (A/G) GT (A/G) CA (T/C) GC 
AS4: TANAG (A/G) CANCC (A/G) GT (A/G) CA (A/G) GC 
N=A,  G, C, T 
An amplified product of the expected size (50 bp) was obtained only 
by the use of the $2 and AS2 primer pair. After polyacrylamide g l 
purification, the amplified product was ligated directly to the pT7Blue 
T-Vector (Novagen). The insert was cut from the amplified vectors 
and used as the screening probe for the rat jejunum eDNA library. 
2.3. cDNA library construction 
Total RNA was extracted from rat jejunum by the acid-guanidi- 
nium thiocyanate-phenol-chloroform (AGPC) method [12]. Poly(A) + 
RNA was isolated using Oligo(dT)-Latex (TaKaRa). Double-stranded 
DNA was synthesized from 5 p~g of rat jejunum poly(A) + RNA by the 
method of Gubler and Hoffman [13] using a eDNA synthesis kit 
(Pharmacia). The eDNA was ligated to EcoRI adaptors and size- 
fractionated in a Sepharose CL-4B column (Pharmacia). The size- 
fractionated eDNA was ligated to 1 ~tg of kZAP II vector arms and 
packaged in vitro using Gigapack III Gold (Stratagene). 
*Corresponding author. Fax: (81) (985) 85-7902. 
The nucleotide sequence reported in this paper has been submitted to 
the GenBank/EMBL DNA database with accession umber U41322. 
2.4. cDNA library screening and sequence analysis 
Hybridization was carried out at 37°C in a solution of 40% forma- 
mide, 6×SSPE (0.9 M NaCI, 50 mM NaH2PO4 (pH 7.4), 5 mM 
EDTA), 5×Denhardt's olution, 0.5% sodium dodecyl sulfate 
(SDS), and 100 ~g/ml denatured salmon sperm DNA. Approx. 
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3 × 105 recombinant phages were transferred to nylon membranes and 
screened using a 50-bp cDNA fragment encoding rat uroguanylin as 
the probe, prepared as described above. The membranes were washed 
twice in 2xSSC (0.3 M NaCI, 30 mM sodium citrate), 0.1% SDS at 
50°C for 30 min. A pBluescript with positive DNA inserts was recov- 
ered from the ;~ZAP II phage by the in vivo excision method with the 
ExAssist helper phage (Stratagene) [14]. The clone (~,RUG23) that 
carried the longest cDNA insert was sequenced by the dyeprimer cycle 
sequencing method in an automated DNA sequencer, Model 373A 
(Applied Biosystems). 
2.5. Peptide synthesis 
Rat uroguanylin-15 (TDECELCINVACTGC), located at the C- 
terminal end of rat preprouroguanylin, was synthesized by solid-phase 
techniques in a peptide synthesizer, Model 430 (Applied Biosystems), 
then purified by reverse-phase high-performance liquid chromatogra- 
phy (RP-HPLC). The correct synthesis was confirmed by amino acid 
analysis and sequencing. Two disulfide bonds at positions 4 and 12, 
and at 7 and 15 were successively inked by a two-step selective form- 
ing reaction. 
2.6. Bioassay for uroguanylin 
cGMP production in T84 cells by synthetic rat uroguanylin was 
investigated. T84 cells were obtained from American Type Culture 
Collection. The cells were grown to confluence in 24-well culture 
dishes at 37°C in a humidified atmosphere containing 5% CO2 with 
a 1:1 mixture of Ham's F-12 medium and Dulbecco's modified Ea- 
gle's medium (DMEM) supplemented with 5% fetal calf serum, peni- 
cillin (100 IU/ml) and streptomycin (100 p.g/ml). A confluent mono- 
layer of T84 ceils was incubated first for 30 rain at 37°C in DMEM 
containing 25 mM HEPES (pH 7.4) and 0.1 mM isobutylmethyl- 
xanthine (IBMX) then for 30 rnin in the same medium containing 
0.1% bovine serum albumin (BSA) and rat uroguanylin-15, rat gua- 
nylin-15, human uroguanylin-16 or E. coli ST (Sigma). After incuba- 
tion, the cGMP concentration i the medium was measured with an 
RIA kit (Yamasa). 
2.7. RNA blot analysis 
Poly(A) + RNA (10 p.g) or total RNA (20 I.tg) was fractionated on a 
1% agarose-formaldehyde gel. After electrophoresis, the RNA was 
transferred to a nylon membrane (Zeta Probe, Bio-Rad) and fixed 
by ultraviolet irradiation (Stratalinker, Stratagene). The membrane 
first was prehybridized at 37°C for 2 h in 50% formamide, 6× SSPE, 
5 × Denhardt's olution, 0.5% SDS, and 100 ~tg/ml denatured salmon 
sperm DNA, then hybridized at 42°C for 18 h in the same buffer 
containing a a2p-labeled cDNA insert of 3,RUG23. The blot was 
washed twice at 60°C in 2×SSC, 0.1% SDS for 30 min, after which 
it was exposed to X-ray film at -80°C. The same membrane was used 
for sequential hybridizations with probes specific for rat guanylin and 
13-actin. 
3. Results 
3.I. cDNA and precursor structure of  rat uroguanylin 
Because the amino acid sequence of rat uroguanylin had 
not been determined, we synthesized primer mixtures repre- 
senting all possible sequences on the basis of the established 
amino acid sequence of human uroguanylin [7] in order to 
amplify the cDNA fragment of rat uroguanylin. A 50-bp 
PCR product was obtained by the use of only one PCR pri- 
mer pair ($2/AS2) when rat jejunum cDNA was the template. 
When the 50-bp PCR product was used as the probe, RNA 
blot analysis revealed that the rat uroguanylin gene was highly 
expressed in the jejunum (data not shown). Therefore, a 
cDNA library for the isolation of clones encoding a urogua- 
nylin precursor was constructed with poly(A) + RNA ex- 
tracted from rat jejunum. A portion of the library (approx. 
3 × 105 recombinant phages) was screened with the amplified 
-36 GCAGAAACCCAGAGGTGTGAGCTGGGAAGCCGGGCC -1 
1ATGTCAGGAAGCCAACTGTGGGCTGCTGTACTCCTGCTGCTGGTGCTGCAGAGTGCCCAG 60 
1MetSerGlySerGInLeuTrpAlaAlaValLeuLeuLeuLeuValLeuGInSerAlaGIn 20 
! 
61GGTGTCTACATCAAGTACCATGGCTTCCAAGTCCAGCTAGAATCGGTGAAGAAGCTGAAT 120 
21GlyValTyrlleLysTyrHisGlyPheGInValGInLeuGluSerValLysLysLeuAsn 40 
121GAGTTGGAAGAGAAGCAGATGTCCGATCCCCAGCAGCAGAAAAGTGGCCTCCTCCCCGAT 180 
41GluLeuGluGluLysGInMetSerAspProGlnGlnGInLysSerGlyLeuLeuProAsp 60 
181GTGTGCTACAACCCCGCCTTGCCCCTGGACCTCCAGCCTGTTTGTGCATCCCAGGAAGCT 240 
61ValCysTyrAsnProAlaLeuProLeuAspLeuGlnProValCysAlaSerGlnGluAla 80 
241GCCAGCACCTTCAAGGCCTTGAGGACCATTGCCACTGATGAATGTGAGCTGTGTATAAAT 300 
81AlaSerThrPheLysAlaLeuArgThrlleAlaThrAspGluCysGluLeuCyslleAsn 100 
301GTTGCCTGTACGGGCTGCTGATGAAATGACTCCAGACACCTACCCCCACAGCCTACCCTG 360 
101ValAlaCysThrGIvCvs*** 106 
361 CCCATACTTAGGTACCATTGACATAATTACCACCCTCCCAGCACAAATGGATCCATAGCA 420 
421 AGACAATATGGATGCAGAGCCGCCATATTTGGTCCCCAGGCAGCTGCACCGG.A.A..T.A..A..A.AA 480 
481 TGTTACCCGC(Doly A) 490 
Fig. 1. Nucleotide sequence of rat uroguanylin cDNA. The termination codon is marked with three consecutive asterisks. The uroguanylin se- 
quence is double underlined. The possible signal peptide is single underlined. The dashed line indicates the polyadenylation signal. 
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Fig. 2. cGMP production in T84 cells by rat uroguanylin-15 (o), 
human uroguanylin-16 (A), rat guanylin-15 (0) and E. coli ST (ll). 
Representative experiment that was repeated twice with the same re- 
suits. 
probe, 6 positive clones being isolated. A second screening of 
these clones gave 3 positive clones. The clone designated 
~RUG23, which harbored the longest cDNA insert (approx. 
550 bp), was sequenced. Fig. 1 shows the complete nucleotide 
sequence of the cDNA which is 526 bp long (excluding the 
poly(A) tail). Two putative initiation methionine codons are 
located in a long open reading frame (nucleotides 1-3, and 
139-141). The initiation codon ATG probably is located at 
nucleotides 1 3 because a highly hydrophobic structure (most 
likely a signal peptide) follows the first methionine. A termi- 
nation codon TGA is present 106 codons later at nucleotides 
319-321, and a consensus polyadenylation signal, AATAAA, 
at nucleotides 467478. 
The deduced amino acid sequence ncoded in the open 
reading frame is shown in Fig. 1, indicating that rat urogua- 
nylin mRNA encodes a 106-residue protein. The nucleotide 
sequence of bases 274-318 corresponds to the amino acid 
sequence of the mature uroguanylin (rat uroguanylin-15), 
which was confirmed by the bioassay using T84 cells. The first 
21-residue peptide, starting from the initial methionine, is 
thought to be a signal peptide because of its characteristic 
hydrophobic features [15]. The first processing of the precur- 
sor probably takes place between Gly 21 and Va122 and gener- 
ates a 85-residue prouroguanylin. 
3.2. cGMP assay for uroguanylin 
We examined the cGMP production of rat uroguanylin-15 
and guanylin-15, human uroguanylin-16 and E. coli ST in 
cultured T84 cells. The four peptides howed a dose-depend- 
ent stimulation of cGMP production between 10 -9 and 10 -6 
M (Fig. 2). The cGMP-stimulating activity of rat uroguany- 
lin-15 at 10 -7 M was almost he same as when rat guanylin-15 
was used as the cGMP stimulant, but less than those of hu- 
man uroguanylin-16 and ST. 
3.3. Distribution of uroguanylin mRNA 
Fig. 3 shows RNA blot analysis of rat uroguanylin. Rat 
uroguanylin mRNA of approx. 600 bases, almost as long as 
that of human uroguanylin [16], was detected in the stomach 
to the colon. A moderate level of rat uroguanylin mRNA was 
observed in the kidney whereas guanylin mRNA was detected 
faintly, and low levels of uroguanylin mRNA in the lung and 
pancreas where no guanylin mRNA was detected (Fig. 3A). 
Rat uroguanylin mRNA is abundant in the upper small in- 
testine, whereas guanylin mRNA shows a gradual increase 
along the duodenum-to-colon axis (Fig. 3B). 
4. Discussion 
Uroguanylin and guanylin are potent physiological regula- 
tors of intestinal fluid and electrolyte transport [1-5]. Their 
structural homologies and similar bioactivities indicate that 
they are members of the same peptide family. In the present 
study, we report the isolation of clones encoding a precursor 
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Fig. 3. RNA blot analysis of the uroguanylin transcript in rat tissues. Each lane contained (A) I0 lag of poly(A) + RNA and (B) 20 ~tg of total 
RNA. Numbers on the left are kilobases as determined from the RNA size markers. The same membrane was used for sequential hybridiza- 
tions with probes for rat guanylin and ~-actin. 
M. Miyazato et aL/FEBS Letters 398 (1996) 170-174 173 
Rat 
Human 
. . . .  KOMS S 5 5 
 CRA LLPGV    L  T S  IO.: O      S AOWAP RL AO 60 
:ii':'iii:'::: :':::':':':~ .:.:.:!.:!':'~/.:.:.:: ':%::.:.:.:':':':?:.:.:.:.~.:':':':':?:.:.:.:.:':?::i ::.:.: :' ':::.:.: . . . .  i':'::'::':?i':'i?:~ :':':: i:::':':':':.:ii::::i :::::::::::::::::::::::::::::::::::::::::::::: Rat ..:..:L , . .  06 
Human "!:': :" :: . . . .  : ::': . . . . . . . . . .  1 1 2 : "  ........................ ' ...................... :: ......... 1 
Fig. 4. Comparison of the amino acid sequences of rat and human uroguanylin precursors. Identical residues are shaded. The putative signal 
peptide cleavage site is indicated by the arrowhead. The uroguanylin sequences are underlined. 
for rat uroguanylin. The deduced amino acid sequence of rat 
uroguanylin precursor was a 106-residue protein. Fig. 4 shows 
the alignment of amino acid sequences of rat and human 
uroguanylin precursors. To maximize the alignment of these 
sequences, five amino acid gaps had to be added to the rat 
sequence. The amino acid sequence homology of rat and hu- 
man uroguanylin precursors is approx. 63%. On the basis of 
the established amino acid and cDNA sequences of human 
uroguanylin [7,16,17], the mature form of rat uroguanylin is 
predicted to be a 15-amino-acid peptide (rat uroguanylin-15) 
located at the end of long preprouroguanylin. I  fact, syn- 
thetic rat uroguanylin-15 increased the cGMP level in T84 
cells. However, its cGMP-stimulating activity is less than 
that of human uroguanylin-16. We found that two conforrna- 
tionally distinct isoforms of human uroguanylin-16 are pro- 
duced during its synthesis; one isoform stimulates cGMP pro- 
duction but another does not [18,19]. In our bioassay, we used 
the bioactive form of human uroguanylin-16, and the mixture 
of bioactive and inactive forms of rat uroguanylin-15. This 
might explain why rat uroguanylin-15 showed almost half of 
the cGMP production compared with human uroguanylin-16. 
Guanylin gene expression is nearly restricted to the intes- 
tine, whereas uroguanylin mRNA is present in the stomach, 
kidney, lung and pancreas in addition to the intestine. 
Furthermore, uroguanylin mRNA is most abundant in the 
upper small intestine, but guanylin mRNA in the colon. These 
results indicate that the two peptides may have different roles 
in the regulation of epithelial function associated with water 
and salt balance. Fan et al. [9] recently reported that opossum 
uroguanylin gene was expressed in the heart, but not in the 
stomach or kidney. We did not detect uroguanylin mRNA in 
rat heart. Species-specific differences in tissue expression of 
uroguanylin gene may explain these disparate data. However, 
the expression level of uroguanylin mRNA in these tissues is 
thought to be much lower than that in the intestine. In situ 
hybridization analysis or the use of more sensitive techniques 
such as PCR could demonstrate gene expression in these tis- 
sues. Evidence for uroguanylin expression in the extra-gastro- 
intestinal tissues uch as lung, kidney and heart indicates that 
uroguanylin may play a pivotal role in the regulation of the 
circulatory system. 
Uroguanylin, as well as guanylin, might be a potent phys- 
iological regulator of intestinal f uid and electrolyte transport. 
However, uroguanylin mRNA was detected not only in the 
intestine but also in the kidney. Intravenous administration of
E. coli ST elicited large increases in urine cGMP excretion and 
urine Na + secretion [20]. These results uggest that uroguanyl- 
in activates GC-C in the kidney and regulates renal fluid and 
electrolyte transport. An intestinal natriuretic factor has been 
sought because oral ingestion of sodium chloride causes a 
dramatic increase in urine salt excretion, whereas the same 
amount of sodium chloride administered intravenously has 
little effect on renal salt excretion [4,21]. The active form of 
uroguanylin is abundant in normal human urine [18], which 
suggests that this peptide links the intestine and kidney in an 
endocrine pathway that controls renal salt metabolism. 
Further investigations of the guanylin family (guanylin and 
uroguanylin) should furnish new insights into the regulation 
of water and electrolyte homeostasis. 
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